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Background: The lower urinary tract symptoms (LUTS) increases with age and can have a significant effect on the
quality of life of the patients. Elderly patients, who are often characterized by a decline in physiological functional
and polypharmacy, are susceptible to adverse drug reactions to pharmacotherapy. LUTS can also be a side effect
of medication. The purpose of this study was to investigate the possible association between the initiation of
LUTS-causing drug therapy and the onset of LUTS.
Methods: Drug dispensing data at the individual level were retrieved from the CISA (Platform for Clinical Information
Statistical Analysis: http://www.cisa.jp) database. A retrospective study was conducted by reviewing patients with LUTS
who were dispensed drugs that increased the risk of LUTS between April 2011 and March 2012. Prescription sequence
symmetry analysis (PSSA) was employed to investigate the associations between the dispensing of medicines of LUTS
and that of LUTS-causing drugs.
Results: LUTS-causing drugs were frequently dispensed to patients with LUTS. The use of medications potentially
contributing to LUTS was associated with polypharmacy [number of prescription drugs:12.13 ± 6.78 (user) vs.
5.67 ± 5.24 (nonuser)] but not patient age [ age: (71.38 ± 13.28 (user) vs. 70.45 ± 14.80 (nonuser)]. Significant adverse
drug events were observed the use of donepezil, cyclophosphamide, antiparkinson drugs, antidepressant, diazepam,
antipsychotic drugs for peptic ulcer, tiotropium bromide, and opioids.
Conclusions: The use of prescription LUTS-causing drugs was correlated with polypharmacy. The adverse drug events
associated with LUTS-causing drugs were highly prevalent in elderly patients. To prevent of adverse drug events
in patients with LUTS, pharmacists and physicians should regularly review medication lists and reduce the
prescribed medicines.
Keywords: Lower urinary tract symptoms, Voiding symptoms, Storage symptoms, Prescription sequence
symmetry analysis, Adverse reactionsBackground
The prevalence of lower urinary tract symptoms (LUTS)
include voiding symptoms and storage symptoms. Voiding
symptoms and storage symptoms are conditions in which
the bladder is unable to store urine properly (storage
symptoms) or empty properly (voiding symptoms) [1].* Correspondence: arai@p.kanazawa-u.ac.jp
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unless otherwise stated.Storage symptoms can show as stress incontinence, urge
incontinence, mixed storage symptoms, or overflow incon-
tinence. Voiding symptoms presents as a wide range of
symptoms that can include difficulty in bladder emptying,
urinary hesitancy, slow or weak urine stream urinary
retention and dribbling of urine. In men, these symptoms
can also be because of an enlarged prostate, a condition
known as benign prostatic hypertrophy (BPH).
The LUTS increases with age and can have a significant
effect on the quality of life [2]. Older individuals frequentlytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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impair continence via direct effects upon lower urinary
tract function, alteration in volume status and urine
excretion, cognitive impairment, and impairment of the
functional ability to use a toilet. The hospitalized eld-
erly with incontinence are more likely to have impaired
mobility, dementia, and delirium and receive psycho-
active medications than their continent patients [3].
Elderly patients, who are often characterized by a
decline in physiological function and polypharmacy, are
susceptible to adverse drug reactions to pharmacotherapy
[4,5]. Poor compliance is most likely to occur among
nonhospitalized patients who receive long-term prescrip-
tions of preventive medications. In addition, 40%–50% of
elderly patients have been unable to take medication as
prescribed by their physicians [6,7].
LUTS can also be a side effect of medication [8,9].
Recently, significant associations between the initiation of
calcium channel blockers, angiotensin-converting enzyme
inhibitors, angiotensin II receptor blockers, hormone
replacement therapies, and hypnotic-sedatives and the
subsequent initiation of oxybutynin, which is used to
manage urgency incontinence, were reported [10]. More-
over, drugs that induce incontinence include alpha 1-
adrenoceptor antagonists, antipsychotics, benzodiazepines,
antidepressants, and hormone replacement therapies in
postmenopausal women [11-13].
Several studies illustrated that individuals with urinary
incontinence are more likely to be using certain medicines,
including antihistamines, beta agonists, angiotensinII recep-
tor blockers, anticonvulsants, and benzodiazepines [14].
But a causal link between the use of these medicines and
urinary incontinence has not been established.
We examined the prescription rate of drugs that can
cause LUTS to patients who ultimately develop LUTS.
In addition, we performed prescription sequence symmetry
analysis (PSSA) to investigate the risk of LUTS caused by
drug side effects.
Methods
Study design and data source
Drug dispensing data at the individual level were retrieved
from the CISA (Platform for Clinical Information Statistical
Analysis: http://www.cisa.jp) database, which contains sub-
stantial clinical information obtained in Japan. Currently,
data from CISA are provided in a fully anonymized form to
14 national university hospitals. In the CISA database, each
prescription record contains basic patient characteristics
(anonymous identifier, gender, and date of birth) and infor-
mation on the drug name, anatomical therapeutic chemical
code, dosage, and dispensing date.
This study identified patients with LUTS who were
coded according to the 10th revision of the International
Statistical Classification of Diseases and Related HealthProblems. Medicines known to cause LUTS were identi-
fied from drug information resources. The Medicines
Handbook [15] was searched to identify medicines with
the adverse drug reaction “LUTS.” Finally, published
articles were identified and reviewed to identify any
additional medicines associated with LUTS. The list of
medicines associated with LUTS that were included in
the study is presented in Table 1.
Medications for LUTS were classified three groups,
drugs for the management of storage symptoms, drugs
for the management of voiding symptoms, and drugs for
the management of mixed urinary dysfunction, as shown
in Additional file 1.
A retrospective study was conducted by reviewing
patients with LUTS who were dispensed drugs associ-
ated with LUTS between April 2011 and March 2012.
The data were stratified to determine the number of
drugs and/or the potential LUTS risk of such drugs used
by patients with LUTS. To determine whether associations
could be detected between the number of medications and
age against the use of LUTS-causing medication, Student’s
t-test was performed to compare the use and nonuse of
targeted medications potentially causing or exacerbating
LUTS.
PSSA
PSSA, as developed by Hallas, is an effective surveillance
tool for drug-associated adverse reactions [16,17]. PSSA
has also been employed in previous studies investigating
associations between the uses of certain targeted drugs.
The validity of PSSA was confirmed by previous research
[18-22].
In PSSA, the date of the first prescription of an LUTS-
causing drug (index drug) and that of the first medication
used to manage LUTS (marker drug) are determined for
each patients. A 6-month “waiting time” was imposed as a
baseline period to ensure that the marker drug was indeed
newly prescribed. The ratio of the number of patients with
initiated LUTS-causing drug therapy before the initiation
of LUTS treatment was compared with the number of
patients who initiated LUTS-causing drug therapy after
the start of LUTS treatment.
Statistical analysis for PSSA
The ratio of patients who initiated marker drug treat-
ment after the initiation of index drug treatment
(index→marker) to those who initiated marker drug
treatment before the initiation of index drug treatment
(marker→ index) was defined as the crude sequence
ratio (SR). PSSA could be sensitive to prescribing trends,
such as rapid increases in marker drug use, over time. To
adjust for such temporal trends, a null-effect SR (SRnull)
was calculated. SRnull is the expected SR in the absence
of a causal association, given the incident medicine use
Table 1 Number of patients with LUTS prescribed
medicines that can cause LUTS
(a) Medicines that caused the storage symptoms
Medication class Medicine Prevalence
n (%)
Anti-dementia drugs Donepezil 272 14.1






Antineoplastic agents Cyclophosphamide 17 1.6
(b) Medicines that caused the voiding symptoms
Medication class Medicine Prevalence
n(%)









Anxiolytics Diazepam 95 4.9
other ※













Other drugs for obstructive
airway diseases, inhalants

















Table 1 Number of patients with LUTS prescribed
medicines that can cause LUTS (Continued)




※The number of patients prescribed the drug was less than 10.
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expected SR of an incidence trend when there is no
causal relationship between the index and marker
drugs, providing a background rate for the chronological
sequence of two drugs. In this study, we computed the
probability of an index drug to marker drug sequence for
each user of an LUTS drug at the first prescription. The
overall probability of a medicine for treating LUTS, Pa,
was generated by weighting the number of incident users
on each prescribing date of drugs for LUTS and averaging
the value over all days. SRnull was then computed as Pa/
(1 – Pa). An adjusted SR was obtained by dividing the
crude SR by SRnull, and 95% confidence intervals (CIs)
were determined with a normal approximation to the
binomial distribution. All analyses were performed using
Ekuseru-Toukei 2012 (Social Survey Research Information
Co., Ltd. Tokyo, Japan).Ethics statement
The study was approved by the Institutional Review Board
of CISA (receipt number: HA1405004).Results
Characteristics of the participants (age, sex, number of
drug prescriptions)
Table 2 shows the characteristics of the participants and
distribution of the types of LUTS. The mean age of the
patients was 70.52 ± 14.60 years, and patients consumed
an average of 6.16 ± 5.38 different medications. The pro-
portion of male patients with voiding symptoms was
large (91.5%). In men, these symptoms can also be because
of BPH.Percentage of prescription agents that were responsible
for urinary disturbance and the efficacy classification
The proportion of patients who were using medications
potentially contributing to urinary symptoms was 7.7%,
with a mean of one incriminating drug per patient
(Table 3). The top five medication classes were donepezil
(14.1% in user of LUTS-causing drugs), antiparkinson
drugs (13.7%), antidepressants (13.8%), antipsychotics
(13.3%), and opiates/narcotics (12.4%) (Table 1).
Table 2 Patient characteristics and frequency of use of medications potentially contributing to urinary symptoms
All Storage symptoms Voiding symptoms Mixed urinary symptoms
Number of patients (%) 17,824 (100%) 5,127 (28.8%) 10,967 (61.5%) 1730 (9.7%)
Male (%) 13,777 (77.2%) 2,159 (42.1%) 10,031 (91.5%) 1,587 (91.7%)
Age (Mean ± SD) 70.52 ± 14.60 64.90 ± 20.00 72.56 ± 10.98 74.22 ± 10.60
Number of prescription drugs (Mean ± SD) 6.16 ± 5.38 6.04 ± 5.58 6.01 ± 5.26 7.50 ± 5.27
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with the use of medications potentially contributing to
urinary symptoms
The use of medications potentially contributing to LUTS
was associated with polypharmacy (12.13 ± 6.78 vs. 5.67 ±
5.24, P value <0.0001) but not patient age (71.38 ± 13.28
vs. 70.45 ± 14.8, P value =0.0244). Among patients with
voiding symptoms, those who used LUTS-causing drugs
were younger than nonusers (69.79 ± 13.58 vs. 72.81 ±
10.71, P value <0.0001). An opposing trend was observed
among patients with storage symptoms (77.35 ± 10.88 vs.
64.30 ± 20.34, P value <0.0001) (Table 3).
Likelihood of incident medicine after initiation of a
medicine that may be associated with LUTS
PSSA identified significant associations between the ini-
tiation of opioids [oxycodone (adjusted SR: 1.20; 95% CI:
1.03–1.41), morphine (adjusted SR: 1.29; 95% CI: 1.14–
1.45)], donepezil (adjusted SR: 1.98; 95% CI: 1.57–2.50),
intestinal lavage solution (adjusted SR: 1.86; 95% CI:
1.65–2.10), cyclophosphamide (adjusted SR: 1.52; 95% CI:
1.14–2.04), levodopa/benserazide (adjusted SR: 1.82; 95%
CI: 1.18–2.81), selective serotonin reuptake inhibitor
(SSRI) [paroxetine (adjusted SR: 1.77; 95% CI: 1.33–2.36)],
serotonin and norepinephrine reuptake inhibitor (SNRI)
[milnacipran (adjusted SR: 2.10; 95% CI: 1.28–3.45)],
diazepam (adjusted SR: 1.73; 95% CI: 1.46–2.06), sero-
tonin dopamine antagonist [risperidone (adjusted SR:
1.55; 95% CI: 1.34–1.79)], levomepromazine (adjusted SR:
2.20; 95% CI: 1.34–1.79), sulpiride (adjusted SR: 1.32; 95%
CI: 1.01–1.72), histamine H2-receptor antagonists [cimeti-
dine (adjusted SR: 1.99; 95% CI: 1.24–3.20)], scopolamine
butylbromide (adjusted SR: 1.72; 95% CI 1.55–1.92), anti-
cholinesterases (tiotropium bromide (adjusted SR: 1.75;
95% CI: 1.42–2.16), cibenzoline (adjusted SR: 2.97; 95%
CI: 1.92–4.59), and amezinium metilsufate (adjusted SR:
1.89; 95% CI: 1.10–3.26) and the subsequent initiation of
medication for managing LUTS (Table 4). When the time
window among the events was restricted to 3 months, the
results were largely consistent with the primary analyses.
Discussion
The number of prescription drugs, but not age, was
significantly different between users (12.13 ± 6.70) and
nonusers (5.67 ± 5.24) of medicines that can cause urin-
ary symptoms.Polypharmacy, inappropriate prescribing, and adverse
drug events are highly prevalent in elderly patients [23].
The characteristics of patients with LUTS included old
age (average age, 70.52 ± 14.60) and male sex. Voiding
symptoms was noted in 57.9% of women, presumably
because of declines in muscle strength, such as pelvic
floor muscle strength, with age. In men, the prevalence
of high outlet obstruction (91.5%) predominated as a
result of prostate enlargement with age.
The typical elderly patient with LUTS typically receives
medication for other comorbidities. Elderly patients taking
five to eight drugs were reported to be at greater risk of
adverse drug reaction related hospitalization than those
taking zero to four drugs [23]. However, a meaningful
correlation was not found between age and the number
of the prescription drugs used by patients with LUTS
(data not shown) in this study. This result may be
responsible for the findings that patients with LUTS
were old (average age, 70.52 ± 14.60) and presented
with several comorbid conditions requiring medication
(average number of prescription drugs, 6.16 ± 5.38).
In total, 7.7% of patients were prescribed medications
potentially contributing to urinary symptoms. Donepezil
(14.1%), antiparkinson drugs (13.7%), antidepressants
(13.8%), and antipsychotics (13.3%) were frequently pre-
scribed, reflecting the rate of complications in older
people. Patients who used medicines that can cause storage
symptoms, such as donepezil, were older than nonusers.
In contrast, patients who used medicines that can cause
voiding symptoms, such as antiparkinson drugs (13.7%),
antidepressants (13.8%), and antipsychotics, were younger
than their nonusing counterparts. The prevalence of
incontinence in the elderly with dementia is higher than
that of persons without dementia. Multiple comorbid dis-
eases, such as depression, Parkinson’s disease, psychotic
disorders, and medications are possible risk factors for
voiding symptoms.
In this study, we demonstrated that the side effects of
donepezil, cyclophosphamide, amantadine, levodopa/ben-
serazide, paroxetine, fluvoxamine,milnacipran, diazepam,
risperidone,levomepromazine,sulpiride, cimetidine, scop-
plamine butylbromide, tiotropium bromide, and opioids
were associated with LUTS. Risperidone therapy has been
associated with storage symptoms (28% in some cases)
[24]. Risperidone primarily acts as an antagonist of sero-
tonin type 2A (5HT2a) and D2-dopamine receptors, and
Table 3 Relationship between age and number of medications used for patients prescribed medications potentially contributing to urinary symptoms
All Storage symptoms Voiding symptoms Mixed urinary symptoms
user nonuser P value user nonuser P value user nonuser P value user nonuser P value
Number of patients (%) 1,365 (7.7%) 16,459 - 234 (4.6%) 4,893 - 907 (8.3%) 10,060 - 224 (12.9%) 1,506 -
Age (Mean ± SD) 71.38 ± 13.28 70.45 ± 14.80 0.0244 77.35 ± 10.88 64.30 ± 20.34 <0.0001 69.79 ± 13.58 72.81 ± 10.71 <0.0001 71.63 ± 12.56 74.60 ± 10.27 0.0002
Number of prescription
drugs (Mean ± SD)















Table 4 Likelihood of incident medicine after initiation of a medicine that may be associated with LUTS (April 2006–J uary 2014)
Medicine Users of
medicine
In the 12 months sequence the 3 months sequence
Index→Marker/
Marker→ Index (n)
Adjusted SR 95% CI dex→Marker/
arker→ Index (n)
Adjusted SR 95% CI
Anti-dementia drugs Donepezil 7,825 210/109 1.98* 1.57–2.50 75/68 1.32 1.00–3.50
Intestinal Lavage Solution Intestinal Lavage Solution 54,014 722/404 1.86* 1.65–2.10 28/228 1.17 1.06–2.82
Decongestants and antiallergics Tranilast 7,161 0/3 NA NA NA NA
Ketotifen 4,644 0/0 NA NA NA NA
Antineoplastic agents Cyclophosphamide 7,787 111/77 1.52* 1.14–2.04 4/62 1.42 0.768–1.55
Antiparkinson Trihexyphenidyl 1,844 24/21 1.14 0.63–2.04 1/13 2 0.804–3.21
Biperiden 3,177 59/41 1.39 0.93–2.07 2/29 1.55 1.33–3.12
Amantadine 2,155 99/65 1.53* 1.12–2.09 6/47 1.42 1.29–2.62
Levodopa/Benserazide 1,652 58/32 1.82* 1.18–2.81 9/15 1.78 1.84–5.86
Antidepressants Mianserin 1,999 73/79 0.94 0.68–1.29 1/65 1.4 0.794–1.56
Paroxetine 9,021 139/70 1.77* 1.33–2.36 20/57 1.37 1.37–2.57
Fluvoxamine 5,178 65/39 1.48 0.99–2.21 2/28 1.56 1.26–3.08
Milnacipran 2,578 52/22 2.10* 1.28–3.45 9/13 1.84 1.82–6.18
Anxiolytic Diazepam 57,776 658/450 1.44* 1.28–1.63 02/336 1.14 1.55–2.02
Antipsychotic Chlorpromazine 4,448 121/117 1.09 0.85–1.41 14/91 1.32 1.00–1.74
Risperidone 14,330 466/310 1.55* 1.34–1.79 91/276 1.16 1.58–2.12
Levomepromazine 2,391 59/26 2.20* 1.34–1.79 5/16 1.77 1.54–4.82
Sulpiride 7,600 126/91 1.32* 1.01–1.72 12/65 1.36 1.21–2.22
Drugs for peptic ulcer Cimetidine 2,886 53/25 1.99* 1.24–3.20 8/18 1.72 1.46–4.30
Scopolamine butylbromide 97,755 909/523 1.72* 1.55–1.92 03/391 1.13 1.57–2.02
Anticholinergic bronchodilator Tiotropium bromide 5,179 234/135 1.75* 1.42–2.16 13/94 1.27 1.80–2.92
Antihistaminic Chlorpheniramine 3,934 6/7 0.87 0.29–2.60 3.72 0.342–4.74
Diphenhydramine 13,073 0/2 NA NA /5 NA NA
Antiarrhythmics Cibenzoline 2,038 81/27 2.97* 1.92–4.59 3/21 1.62 2.12–5.59
Cardiac stimulants excl. cardiac glycosides Amezinium metilsulfate 1,665 38/20 1.89* 1.10–3.26 4/13 1.89 1.38–4.94
Droxidopa 650 15/17 0.90 0.45–1.79 3/11 2.23 0.537–2.68










































Table 4 Likelihood of incident medicine after initiation of a medicine that may be associated with LUTS (April 2006–January 2014) (Continued)
Opioids Morphine 20,378 599/449 1.29* 1.14–1.45 564/370 1.14 1.29–1.68
Codeine phosphate 11,223 234/223 1.04 0.86–1.25 192/137 1.25 1.11–1.72
Oxycodone 6,370 334/289 1.20* 1.03–1.41 333/176 1.2 1.64–2.37
NA: Not applicable. *Statistical significant at an alpha level of 0.05.
Index→Marker (causal): patients initiated marker drug therapy after initiating index drug treatment.
Marker→ Index (noncausal): patients initiated index drug therapy after initiating marker drug treatment.
Index drug: Medicine associated with a risk of LUTS. Marker drug: Medication for treating LUTS.
Number of participants who initiated a medicine associated with LUTS between 2005 and 2013.
Sequences of the incident index and marker drugs within 3 or 12 months.
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receptors. It may be that the antagonizing effect of ris-
peridone on the α-1 receptors of the internal bladder
sphincter causes urinary retention [25]. Levomepromazine
also may affect the α-1 receptors of the internal bladder
sphincter.
Sulpiride, a D2-selective dopaminergic receptor antagon-
ist, increased bladder capacity in rats [26]. Dopaminergic
systems have also been implicated in the control of the
micturition reflex. D1-like dopaminergic receptors medi-
ate forebrain-inhibitory effects on the micturition reflex,
whereas D2-like dopaminergic receptors appear to be
involved in excitatory regulation of the micturition reflex
at the level of the brainstem. The prevalence of LUTS in
patients with Parkinson disease (PD) is reported to be
27%–39% [27]. Levodopa is well established as the most
effective drug for the symptomatic treatment of idiopathic
or Lewy body PD. Amantadine is known to increase dopa-
mine release, inhibit dopamine reuptake, and stimulate
dopamine receptors, and it may possibly exert central
anticholinergic effects [27].
Anticholinergic agents such as biperiden and trihexy-
phenidyl did not display meaningful peripheral antimus-
carinic side effects. In contrast, the dopamine-related
drugs levodopa and amantadine exerted side effects, sug-
gesting that LUTS caused by such drugs is dependent
on dopaminergic activity.
Milnacipran, a dual-action antidepressant that acts as a
serotonin and norepinephrine reuptake inhibitor (SNRI),
and paroxetine, a selective serotonin reuptake inhibitor
(SSRI), have been linked to voiding symptoms. Animal
studies suggested that incontinence secondary to sero-
tonergic antidepressants could be mediated by 5HT4
receptors found on the bladder [28,29]. These drugs
may affect serotonin uptake by 5HT receptors found on
the bladder. Recently, experiments in cats illustrated that
SNRIs suppress parasympathetic activity and increase
sympathetic and somatic neural activity in the lower
urinary tract [30]. The inhibition of serotonin and nor-
epinephrine reuptake during bladder storage is believed
to increase pudendal nerve output, resulting in increased
tone of the rhabdosphincter and subsequently improved
urethral closure. The SNRI duloxetine can significantly
improve the quality of life of patients with stress urinary
incontinence. In this study, voiding symptoms was caused
by milnacipran, suggesting that milnacipran-associated
voiding symptoms may have beneficial effects on urinary
incontinence.
The most common medication class potentially con-
tributing to LUTS is benzodiazepines (17.4%) [31]. The
mechanism by which other medicines cause incontin-
ence is the activation of N-methyl-D-aspartate receptors
in pontine micturition center (PMC) that are involved in
the facilitation of voiding [32].Men with LUTS or BPH who are treated with inhaled
anticholinergic agents may develop acute urinary reten-
tion, but this cannot be quantified on the basis of the
limited information available. Inhaled anticholinergic agents
should be used when indicated in men with LUTS or BPH
but close monitoring and patient education should be
implemented [33]. Inhaled anticholinergic medication
use in older men with chronic obstructive pulmonary
disorder is associated with an increased risk of acute
urinary retention [34].
The prevalence of opioid-induced dysuria in patients with
advanced cancer-associated pain was 14.9% [35]. Urinary
retention induced by systematically injected morphine was
considered to result from the inhibition of bladder function
mediated via μ-opioid receptors of the micturition centers
in the supraspinal and spinal regions [36].
Dementia and storage symptoms are common, and often
coexisting, problems in older people. Anticholinergic drugs
are used to treat urinary instability [37-39]. In this study,
storage symptoms is expected to occur in patients treated
with donepezil. The potential for worsened urinary contin-
ence is an important consideration when starting cholin-
esterase treatment in Alzheimer disease (AD).
Cyclophosphamide is metabolized to several moieties,
including acrolein, which collects in the urinary bladder,
leading to urothelial damage [40]. Cyclophosphamide
causes cellular damage in bladder tissue that triggers an
inflammatory response. Therefore, cyclophosphamide is
commonly used in noninvasive rodent models of acute
bladder pain [41].
The current study has highlighted the potential for the
initiation of commonly used medicines to be associated
with the subsequent initiation of drug treatment for
LUTS and has provided an estimate of the risk of LUTS
associated with these medicines. Prescribers should be
aware of LUTS that occurs shortly after the initiation of
new medicines, and the potential for an adverse event
should be considered. For this reason, before the treat-
ment for LUTS is started, the possible side effects of
medications currently used for the patient should be
reviewed and the planned treatment for LUTS should be
adjusted if necessary.Conclusions
We found that medicines that can cause urinary symp-
tom were prescribed to patients taking many drugs and
were associated with an increased risk of LUTS. The
findings illustrated that polypharmacy and adverse drug
events associated with LUTS-causing drugs were highly
prevalent in patients with LUTS. In addition, our study
provides a basis for future investigations of whether
milnacipran-associated voiding symptoms may be useful
for the treatment of storage symptoms.
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